Afatinib News and Research

RSS

Newly identified gene drives development of the second most common type of lung carcinoma

A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might someday be treated.

9 Jan 2023

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Automated computational protocol identifies potential SARS-CoV-2 MPro inhibitor

As scientists race to discover new and effective antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many novel approaches are being utilized. Now, a new study published on the preprint bioRxiv in September 2020 reports on the discovery of a potentially beneficial enzyme blocker that could inhibit SARS-CoV-2 viral replication.

24 Sep 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

Gero uses AI platform to identify potential anti-COVID-19 drugs

Gero, the leader in AI-driven drug discovery, has used its AI platform to identify the potential anti-COVID-19 drugs. Six of them have been approved, three were withdrawn, and the other nine have been already tested in clinical trials for other indications.

25 Mar 2020

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

20 Aug 2019

Blood-based liquid biopsies can accurately track cancer treatment responses

Results of two clinical studies have added to evidence that blood-based liquid biopsies can accurately track lung cancer treatment responses by measuring circulating tumor DNA (ctDNA) during immunotherapy and related treatments.

14 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

Scientists discover genetic causes underlying group of related infant cancers

The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators.

18 Jun 2018

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research.

16 May 2018

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC).

5 Jun 2017

Penn studies provide new understanding of lung cancer progression and prevention

Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

16 Mar 2017

Gene expression patterns could help predict treatment for breast cancer, research shows

A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.

21 Feb 2017

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy.

19 Aug 2016

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors.

22 Jun 2016

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.

21 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Post-progression afatinib exposure boosts NSCLC outcomes

Continued exposure to afatinib plus paclitaxel can benefit non-small-cell lung cancer patients who developed resistance to erlotinib or gefitinib and progressed after initially responding to afatinib monotherapy, suggest phase III trial results.

11 Dec 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015